Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University
Tonix Pharmaceuticals presented positive Phase 1 data for TNX-4800, a long-acting monoclonal antibody designed to prevent Lyme disease, and outlined plans for an adaptive Phase 2 field study to begin in the first half of 2027. The planned Phase 2 study will test a two-dose subcutaneous regimen with the primary endpoint of preventing Lyme disease for six months following the initial dose.
Key figures
- Drug Name
- TNX-4800
- Phase Of Trial
- Phase 1 (completed), Phase 2 (planned H1 2027)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.